BACKGROUND: Prostate-specific membrane antigen (PSMA) remains an active target for imaging and therapeutic applications for prostate cancer. METHODS: In the present study, an irreversible phosphoramidate inhibitor, CTT-54 (IC50 = 14 nM), has been modified to deliver 99mTc-(CO)3-DTPA as a SPECT imaging payload to PSMA+ cells in vivo and in vitro. Percent uptake, competitive binding, and internalization will evaluate the imaging agent in vitro. Preliminary biodistribution and imaging will be utilized for in vivo evaluation. RESULTS: In vitro studies demonstrate that the radiotracer 99mTc-(CO)3-DTPA-CTT-54 exhibits increasing cellular uptake in the PSMA+ LNCaP cells over time. More importantly, it was found that 99mTc-(CO)3-DTPA-CTT-54 is rapidly internalized into LNCaP cells, presumably through the PSMA enzyme-inhibitor complex. In a pilot biodistribution study, increasing accumulation of the radiotracer in LNCaP xenografts was observed from 2 to 4 hr and significant clearance from non-target tissues. CONCLUSIONS: While DTPA may not represent the ideal chelate structure for 99mTc(CO)3, the data provides proof-of-concept support for the development of a next-generation phosphoramidate-based PSMA inhibitor-conjugates for use as SPECT imaging agents.
BACKGROUND:Prostate-specific membrane antigen (PSMA) remains an active target for imaging and therapeutic applications for prostate cancer. METHODS: In the present study, an irreversible phosphoramidate inhibitor, CTT-54 (IC50 = 14 nM), has been modified to deliver 99mTc-(CO)3-DTPA as a SPECT imaging payload to PSMA+ cells in vivo and in vitro. Percent uptake, competitive binding, and internalization will evaluate the imaging agent in vitro. Preliminary biodistribution and imaging will be utilized for in vivo evaluation. RESULTS: In vitro studies demonstrate that the radiotracer 99mTc-(CO)3-DTPA-CTT-54 exhibits increasing cellular uptake in the PSMA+ LNCaP cells over time. More importantly, it was found that 99mTc-(CO)3-DTPA-CTT-54 is rapidly internalized into LNCaP cells, presumably through the PSMA enzyme-inhibitor complex. In a pilot biodistribution study, increasing accumulation of the radiotracer in LNCaP xenografts was observed from 2 to 4 hr and significant clearance from non-target tissues. CONCLUSIONS: While DTPA may not represent the ideal chelate structure for 99mTc(CO)3, the data provides proof-of-concept support for the development of a next-generation phosphoramidate-based PSMA inhibitor-conjugates for use as SPECT imaging agents.
Authors: Sangeeta Ray Banerjee; Zhengping Chen; Mrudula Pullambhatla; Ala Lisok; Jian Chen; Ronnie C Mease; Martin G Pomper Journal: Bioconjug Chem Date: 2016-05-09 Impact factor: 4.774
Authors: Lisa Y Wu; Jacqueline M Johnson; Jessica K Simmons; Desiree E Mendes; Jonathan J Geruntho; Tiancheng Liu; Wessel P Dirksen; Thomas J Rosol; William C Davis; Clifford E Berkman Journal: Prostate Date: 2014-01-21 Impact factor: 4.104
Authors: Benjamin B Kasten; Tiancheng Liu; Jessie R Nedrow-Byers; Paul D Benny; Clifford E Berkman Journal: Bioorg Med Chem Lett Date: 2012-11-16 Impact factor: 2.823
Authors: Sangeeta Ray Banerjee; Mrudula Pullambhatla; Catherine A Foss; Alexander Falk; Youngjoo Byun; Sridhar Nimmagadda; Ronnie C Mease; Martin G Pomper Journal: J Med Chem Date: 2013-07-22 Impact factor: 7.446
Authors: Jessie R Nedrow-Byers; Adam L Moore; Tanushree Ganguly; Mark R Hopkins; Melody D Fulton; Paul D Benny; Clifford E Berkman Journal: Prostate Date: 2012-08-21 Impact factor: 4.104
Authors: A P Kiess; S R Banerjee; R C Mease; S P Rowe; A Rao; C A Foss; Y Chen; X Yang; S Y Cho; S Nimmagadda; M G Pomper Journal: Q J Nucl Med Mol Imaging Date: 2015-07-24 Impact factor: 2.346
Authors: Shorouk Dannoon; Tanushree Ganguly; Hendry Cahaya; Jonathan J Geruntho; Matthew S Galliher; Sophia K Beyer; Cindy J Choy; Mark R Hopkins; Melanie Regan; Joseph E Blecha; Lubica Skultetyova; Christopher R Drake; Salma Jivan; Cyril Barinka; Ella F Jones; Clifford E Berkman; Henry F VanBrocklin Journal: J Med Chem Date: 2016-06-13 Impact factor: 7.446